Navigation Links
Misonix Announces Exclusive U.S. Distribution Agreement For Advanced Wound Care Product
Date:6/1/2011

fficer of Misonix. "Anika's Hyalomatrix skin substitute will hold an important position in our treatment protocol for advanced wound management and is synergistic to our own SonicOne product line.

"This Agreement demonstrates the Company's continued commitment to growth in large markets either by organic growth or the distribution of synergistic world class products through our domestic sales forces.  The addition of Hyalomatrix is consistent with our plan to leverage the value of our existing distribution organization by adding more high value products to our sales pipeline."

About Misonix:  Misonix, Inc. (NASDAQ: MSON) designs, manufactures and markets therapeutic ultrasonic medical devices.  Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies.  Addressing a combined market estimated to be in excess of $3 billion annually, Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated
'/>"/>

SOURCE Misonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
2. Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results
3. Misonix, Inc. Announces the Sale of Sonora Medical Systems for $8 Million
4. Misonix Announces New Distribution Agreement for United Kingdom and Republic of Ireland
5. Misonix Announces New Distribution Agreement for Mexico
6. Misonix Schedules First Quarter 2010 Financial Results Conference Call; November 16, 2009 at 4:30 p.m. Eastern
7. Misonix Announces New Distribution Agreement for Saudi Arabia and Other Middle Eastern Countries
8. Misonix Announces New Distribution Agreement for Peru
9. Misonix Announces New Distribution Agreement For The United Arab Emirates (UAE)
10. Misonix Announces New Distribution Agreement for Argentina
11. Misonix Announces New Distribution Agreement for Kingdom of Saudi Arabia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
(Date:4/23/2014)... Oncotarget , explored tumour heterogeneity where ... DNA signatures within the same cancer. Such differences ... treatment strategies. , Firstly they confirmed the mutual ... KRAS or BRAF mutation. Secondly, they found that ... have that specific mutation present uniformly throughout the ...
(Date:4/23/2014)... of endogenous neural precursor cells cannot alone compensate ... the perspective of neural plasticity, Dr. Yun Xiang ... observed the effects of functional electrical stimulation treatment ... of basic fibroblast growth factor and epidermal growth ... side. The researchers found that functional electrical stimulation ...
(Date:4/22/2014)... the United States with 1 million participants annually. A ... Injury Research and Policy at Nationwide Children,s Hospital is ... distribution patterns of basketball-related injuries treated in emergency departments ... and teens. , The study, published online in the ... to adolescents 13-19 years of age who were treated ...
(Date:4/22/2014)... recently FDA-approved device has been shown to reduce seizures ... 50 percent. When coupled with an innovative electrode placement ... facilitated the complete elimination of seizures in nearly half ... clinical trials. , That,s good news for a large ... living with epilepsy whose seizures can,t be controlled with ...
(Date:4/22/2014)... that can provide primary care for low-income patients ... and insurance companies while improving patient health, researchers ... suggests that health clinics that avoid costs associated ... by lowering hospital admission rates and emergency room ... Penn State Altoona. , The researchers estimated ...
Breaking Medicine News(10 mins):Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2
... recommended treatments, study found , FRIDAY, May 28 (HealthDay ... designed to review current research and guidelines, doctors made ... patients with high blood pressure, a new study reports. ... reflected in the practices of community physicians remains a ...
... Chase Cancer Center investigators find that pancreatic cancer patients who ... patients without circulating tumor cells. Additionally, the team has uncovered ... and some may predict worse outcomes than others. Benjamin ... will present the study at the 46th Annual Meeting of ...
... the final details on how two stroke-prevention procedures are safe ... stroke, though their effectiveness does vary by age, say researchers ... Public Health in collaboration with other North American stroke investigators. ... Journal of Medicine (NEJM) May 26, the researchers say ...
... ... range of crystalens to benfit the patients. , ... (Vocus) -- Dr. Khanna and crystal lens have had a symbiotic relationship ... has especially been helpful in people who have undergone radial RK or macular degeneration. ...
... to be self-centered, competitive, U.S. research shows , FRIDAY, May ... reveals that American college students are not quite as empathetic ... drop in empathy after the year 2000," co-author Sara Konrath, ... Research, said in a news release. "College kids today are ...
... brain, still befuddles patients and researchers, , FRIDAY, May 28 ... be a lifeline to the future. And more aggressive, high-dose ... there,s a downside, too: Chemotherapy is linked to a mental ... dismissed as "all in your head," but that,s no longer ...
Cached Medicine News:Health News:Putting New Medical Guidelines Into Practice Often Difficult 2Health News:Circulating tumor cells correlate with poorer survival in pancreatic cancer patients 2Health News:Age is a factor in choosing between two comparable stroke-prevention procedures 2Health News:Khannna Institute to offer Crystalens in Quarter Diopter Steps 2Health News:Today's College Students More Likely to Lack Empathy 2Health News:Making Your Way Through the Fog of Chemotherapy 2Health News:Making Your Way Through the Fog of Chemotherapy 3
Cushing periosteal elevators, rounded edge, sharp, wide, blade width 5/8" (16 mm), length 7 1/4" (184 mm)....
Barr periosteal elevators....
Molt 9 periosteal elevators....
Miller Collburn periosteal elevators....
Medicine Products: